ArticleGland surgery2026
Biochemical and clinical remission after adrenalectomy in patients with primary aldosteronism: a retrospective two-center study.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary hyperaldosteronism (PHA) is a common condition with a prevalence of around 11% in the hypertensive population. For unilateral PHA, the preferred treatment approach is adrenalectomy with the objective to normalize aldosterone levels and its associated harmful effects. However, the reported biochemical outcomes after adrenalectomy vary widely within the literature. This study aimed to evaluate the biochemical and clinical remission rates after unilateral adrenalectomy in patients with PHA. Methods: We conducted a retrospective study in two academic centers in Switzerland to evaluate the biochemical and clinical remission rate in patients who underwent unilateral adrenalectomy for confirmed PHA. Biochemical remission was defined as the normalization of aldosterone levels after surgery. Clinical remission was achieved when the patient was able to stop potassium substitution and/or reduce the antihypertensive therapy postoperatively. Results: Eighty-two patients (51 male, mean age 49.6 years) who underwent unilateral adrenalectomy for PHA from January 2006 to December 2017 were included. Arterial venous sampling (AVS) before surgery was performed to confirm unilateral disease in 88% of patients. AVS results were concordant with the adrenal lesion seen on imaging in all cases. Histology showed an adenoma in 75.6%, and unilateral hyperplasia in 20.7% of cases. Adrenalectomy significantly reduced aldosterone levels (P<0.001) and 91.2% of patients were able to stop potassium substitution. Antihypertensive therapy was discontinued in 53.6% of patients, while the remaining had a significant reduction in mean number of antihypertensive drugs (2.92 Conclusions: In our cohort, unilateral adrenalectomy resulted in biochemical response in 95.1% of patients and complete clinical success with discontinuation of antihypertensive therapy in 53.6%, supporting surgery as an effective treatment for unilateral primary aldosteronism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.